circPAN3, which is expressed in resistant AML cells, enhances autophagy levels by the regulation of the AMPK/mTOR pathway, making circPAN3 a new therapy target in relapsed AML [297]. The gene discussed is MTOR; the disease is acute myeloid leukemia.